---
document_datetime: 2023-09-21 17:15:28
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/neorecormon-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: neorecormon-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.79002
conversion_datetime: 2025-12-14 23:22:37.522955
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## PROCEDURAL STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

For procedures finalised after 1 April 2004 please refer to module 8B.

- On 2 April 1998, the European Commission approved a variation (Type I following type II) for the serum-free production of Epoetin beta.
- On 2 April 1998, the European Commission approved an Annex II application (Extension of the Marketing Authorisation) for 7 additional strengths/pharmaceutical forms (solution for injection).  The  relevant  amendments  have  been  incorporated  in  the  relevant  sections  of  the Commission Decision and of this EPAR.
- On 1 October 1998, the European Commission approved a type I variation submitted by the company  relating  to  the  change  of  name  of  the  solution  for  injection  presentations  to 'NeoRecormon  &lt;strength&gt;  IU  solution  for  injection  in  pre-filled  syringe'.  The  relevant amendments have been incorporated in the relevant sections of the Commission Decision and of this EPAR.
- On 11 November 1998, the European Commission approved a type II variation for the extension of the shelf life to 3 years at 2 - 8 Â°C for NeoRecormon (powder and solvent for solution for injection) for the following strengths: 500 IU, 1000 IU, 2000 IU, 5000 IU and 10000 IU single dose and 50000 IU and 10000 IU multidose. The relevant amendments have been incorporated in the relevant sections of the Commission Decision and of this EPAR.
- On 11 November 1998, the European Commission approved a type II variation to change the needle size for NeoRecormon in pre-filled syringe and to update the SPC, PL and labels for all presentations. The relevant amendments have been incorporated in the relevant sections of the Commission Decision and of this EPAR.
- On 2 July 1998, the European Commission notified the EMEA, the Marketing Authorisation Holder and the members of the Standing Committee of a type I variation (change in bulk buffer) which does not require any amendment to the Commission Decision.
- On 7 May 1999 (date of notification: 12 March 1999), the European Commission approved a transfer  of  Marketing  Authorisation  from  Boehringer  Mannheim  GmbH  (Germany)  to  Roche Registration Ltd. (United Kingdom). The relevant amendments have been incorporated in the relevant sections of the Commission Decision and of this EPAR.
- On  1  July  1999,  the  European  Commission  approved  a  type  I  variation:  changes  following modification  of  the  manufacturing  authorisation  (transfer  of  Marketing  Authorisation).  The relevant  amendments  have  been  incorporated  in  the  relevant  sections  of  the  Commission Decision and of this EPAR.
- On  16  July  1999,  the European  Commission  approved  a  type  II  variation:  additional manufacturing site for the  NeoRecormon  pre-filled syringes  500  IU-20000  IU  (Roche Diagnostics  GmbH,  Mannheim).  The  relevant  amendments  have  been  incorporated  in  the relevant sections of this EPAR.
- On 10 February 2000, the European Commission approved a type II variation: changes to SPC, labelling  and  package  leaflet  with  regards  to  new  template,  amendments  to  sections  4.8  as a result of second PSUR and update of the addresses of local representatives in package leaflet. The relevant amendments have been incorporated in the relevant sections of the Commission Decision and of this EPAR.
- On  10  February  2000,  the  European  Commission  approved  three  Annex  II  application (Extension  of  the  Marketing  Authorisation)  for  2  additional  strengths  of  the  solution  for injection in pre-filled syringes and 1 additional strength of the powder and solvent for solution for  injection  in  cartridge.  The  relevant  amendments  have  been  incorporated  in  the  relevant sections of the Commission Decision and of this EPAR.

<div style=\"page-break-after: always\"></div>

- On  20  March  2001,  the  European  Commission  approved  a  type  II  variation:  additional indication.  The  relevant  amendments  have  been  incorporated  in  the  relevant  sections  of  the Commission Decision and of this EPAR.

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                                                                                                                              | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amen ded on   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|------------------------------------------|
| Change to summary of product characteristics (section 4.2) and package leaflet to update the posology section in order to include a new, once weekly, frequency of administration. | II/15                | II                       | 31.05.01                            | 17.09.01                                 |
| Change in the batch size of finished product                                                                                                                                       | I/16                 | I                        | 14.05.01                            |                                          |
| Change in test methods for the active substance                                                                                                                                    | II/17                | II                       | 27.06.01                            | 04.07.01                                 |
| Change in test procedures of the medicinal product                                                                                                                                 | I/II/18              | I/II                     | 27.06.01                            | 06.07.01                                 |
| Change in specifications for the active substance                                                                                                                                  | II/19                | II                       | 15.11.01                            | 19.11.01                                 |
| Minor change in labelling and package leaflet not connected with the SPC (Art. 61(3) Notification)                                                                                 | N/20                 | N                        |                                     | 29.09.01                                 |
| Minor change in manufacturing of the medicinal product                                                                                                                             | I/21                 | I                        | 21.02.02                            | 01.03.02                                 |
| Renewal                                                                                                                                                                            | R/22                 | R                        | 28.05.02                            | 22.08.02                                 |
| Change to summary of product characteristics (section 4.2) and package leaflet to update the posology section in order to include a new, once weekly, frequency of administration. | II/23                | II                       | 21.08.02                            | 03.12.02                                 |
| Additional secondary packing site                                                                                                                                                  | I/24                 | I                        | 25.10.02                            | 05.11.02                                 |
| Update of Summary of Product Characteristics and Package Leaflet                                                                                                                   | II/26                | II                       | 18.12.02                            | 17.03.03                                 |
| Additional secondary packing site                                                                                                                                                  | I/27                 | I                        | 25.10.02                            | 05.11.02                                 |
| Additional secondary packing site                                                                                                                                                  | I/28                 | I                        | 08.11.02                            | 08.11.02                                 |
| Change in the batch size of finished product                                                                                                                                       | I/29                 | I                        | 23.01.03                            | 27.01.03                                 |
| Change(s) to the manufacturing process for the active substance                                                                                                                    | II/30                | II                       | 25.04.03                            | 30.04.03                                 |
| Addition of new strength                                                                                                                                                           | X/31                 | X                        | 25.09.03                            | 23.02.04                                 |

1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II application.

T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992.

2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.

2/2